
    
      Study Procedures:

      Initial screening period:

      HCV GT2K/1B -infected subjects who will be meeting eligibility criteria, will provide written
      informed consent, perform baseline RAS testing and will be enrolled to the study.

      Baseline period:

      On day 0, all patients will be assessed by a general physical examination, blood and urine
      tests including HCV resistance mutations (elaborated in the budget file), Fibroscan or SHEAR
      WAVE Elastography and abdominal ultrasound. After the initial assessment all included will be
      allocated for treatment.

      Study configuration:

      The study will include 1 group of patients infected GT 2k1b. Patients will be treated
      according to label recommendation for GT1b (with and without cirrhosis) for 12 weeks. All
      subjects will receive Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir. Scheduled visits will
      take place in 0, 4, 12 and 24 weeks for all patients.

      All visits will include: physician assessment and blood tests as elaborated in the Study
      Flowchart. Subjects will be assessed for antiviral response, clinical outcomes, patient
      reported adverse events and presence and emergence of resistance associated variants.
    
  